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Background: Signal transducer and activator of transcription 3 (STAT3) is an important transcriptional factor
frequently associated with the proliferation and survival of a large number of distinct cancer types. However, the
signaling pathways and mechanisms that regulate STAT3 activation remain to be elucidated.
Methods: In this study we took advantage of existing cellular models for chronic myeloid leukemia resistance,
western blot, in vitro signaling, real time PCR, flow cytometry approaches for cell cycle and apoptosis evaluation
and siRNA assay in order to investigate the possible relationship between STATIP1, STAT3 and CML resistance.
Results: Here, we report the characterization of STAT3 protein regulation by STAT3-interacting protein (STATIP1) in
the leukemia cell line K562, which demonstrates constitutive BCR-ABL TK activity. K562 cells exhibit high levels of
phosphorylated STAT3 accumulated in the nucleus and enhanced BCR-ABL-dependent STAT3 transcriptional activity.
Moreover, we demonstrate that STATIP1 is not involved in either BCR-ABL or STAT3 signaling but that STATIP1 is
involved in the down-regulation of STAT3 transcription levels; STATIP1-depleted K562 cells display increased proliferation
and increased levels of the anti-apoptosis STAT3 target genes CCND1 and BCL-XL, respectively. Furthermore, we
demonstrated that Lucena, an Imatinib (IM)-resistant cell line, exhibits lower STATIP1 mRNA levels and undergoes
apoptosis/cell cycle arrest in response to STAT3 inhibition together with IM treatment. We provide evidence that
STATIP1 siRNA could confer therapy resistance in the K562 cells. Moreover, analysis of CML patients showed an
inverse expression of STAIP1 and STAT3 mRNA levels, ratifying that IM-resistant patients present low STATIP1/high
STAT3 mRNA levels.
Conclusions: Our data suggest that STATIP1 may be a negative regulator of STAT3 and demonstrate its
involvement in IM therapy resistance in CML.
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The signal transducer and activator of transcription 3
(STAT3) protein belongs to a class of transcription factors
that are activated by a number of growth factors and
oncogenic proteins [1]. The activation of STAT3, which is
regulated by the phosphorylation of tyrosine 705, is driven
by receptor and non-receptor protein tyrosine kinases
(TK), such as EGFR, gp130, Ras, Src and Abl [2-5]. Once
activated, STAT3 forms homodimers, translocate to the
cell nucleus and binds to specific regulatory DNA ele-
ments to induce transcription. Under physiologic condi-
tions, the activation of STAT3 is transient and rapid [6].
However, the persistent activation of STAT3 protein has
been associated with several hematological cancers and
solid tumors [7]. Previous data suggest that the constitutive
activation of STAT3 induces cell transformation by the up-
regulation of anti-apoptotic and cell proliferation-related
genes, such as BCL-XL and CCND1 [7], and oncogenes,
such as PIM1 and c-Myc [8,9]. Furthermore, STAT3 acti-
vation has been associated with the up-regulation of VEGF
and TWIST1, genes related to angiogenesis and metastasis
[10]. These findings suggest a straight relationship between
STAT3 activation and cancer development.
In chronic myeloid leukemia (CML), the chimeric onco-
protein BCR-ABL, a constitutively activated TK, promotes
the malignant transformation of hematopoietic cells [11].
BCR-ABL leads to the constitutive activation of the JAK/
STAT, Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR
signaling pathways [12-14]. In CML, persistent STAT3
phosphorylation mediated by BCR-ABL has been associ-
ated with cellular proliferation, the inhibition of apoptosis
and chemotherapy resistance [5,15-19]. Although it is
clear that the signaling activity of BCR-ABL is the main
cause of the neoplastic transformation, the precise
mechanisms by which BCR-ABL transforms cells re-
main largely unknown. Thus, strategies designed to
understand the transcriptional activity of STAT3 may
be important tools for discovering the next generation
of anti-leukemia therapies.
STAT3 is negatively regulated by the suppressors of
cytokine signaling proteins, known as SOCS, by protein
inhibitor of activated STAT, known as PIAS, or by phos-
phatases, known as SHP. However, the regulatory mech-
anisms that negatively modulate STAT3 are ineffective
in cancers [20]. Thus, several studies have tried to iden-
tify proteins that could interact and positively or nega-
tively regulate STAT3 activity [21-28].
Although many proteins are known to interact and
regulate STAT3 activity, the mechanisms surrounding
such regulation of the STAT3 protein remain to be eluci-
dated in CML. Collum and cols. [29] described STAT3-
interacting protein 1 (STATIP1) as a STAT3-associated
protein. STATIP1 contains 12 WD40 domains that medi-
ate protein-protein interactions, which play importantroles in the regulation of signal transduction, transcription
and proteolysis [30]. STATIP1 overexpression blocked
STAT3 activation in the human hepatocellular carcinoma
cell line HepG2 [29], suggesting a negative role for STA-
TIP1 in STAT3 regulation. However, neither the STATIP1
expression nor its potential to regulate STAT3 activity has
been assessed to date in other cancer types, such as
leukemia cells. To address this issue, the aim of this study
was to evaluate the STATIP1 and STAT3 status in the
well-characterized CML model. Using K562 cell line, we
report that STATIP1 may act as a negative regulator of
STAT3 transcriptional activity in CML and reduce the ef-
fects of Imatinib (IM) in K562 cells. Moreover, using a
CML multidrug resistance (MDR)/Imatinib resistant cell
line (Lucena) and CML patients’ samples we address the
relationship of STATIP1 and STAT3 in IM resistance. Our
results suggest a new role for STATIP1 in CML thera-
peutic resistance.
Methods
Cell lines and drug treatments
A CML model cell line, K562, was cultured in RPMI-
1640 medium containing 10% fetal bovine serum, 100
U/ml penicillin and 100 μg/ml streptomycin in 5% CO2 at
37°C. Lucena cells [K562 MDR/IM resistant cell line in-
duced by vincristine] overexpressing ABCB1 were kindly
provided by Dra. Vivian Rumjanek (Departamento de Bio-
química Médica, Universidade Federal do Rio de Janeiro,
Brazil) [31]. The Lucena cells were cultured in the same
conditions as the K562 cells, but its medium was supple-
mented with 60 nM VCR (Sigma).The K562 cells were
plated at 1 × 105 cells/ml. The inhibition of BCR-ABL ac-
tivity by treatment with IM (imatinib mesylate, Novartis)
was performed using a final concentration of 1 μM for
24 h. For STAT3 inhibition, 40 μM LLL-3 was applied to
culture for 24 h. The LLL-3 was kindly provided by Dr.
Pui-Kai Li from Ohio State University, USA.
Patients samples
This study was approved by the ethics committee of the
National Cancer Institute Hospital (INCA, Rio de Janeiro,
Brazil). Patients were admitted or registered at the
National Cancer Institute Hospital, according to the
guidelines of its Ethics Committee and the Helsinki dec-
laration. All patients and healthy donors were adults and
signed the consent form. Bone marrow samples were
obtained from CML patients in all disease phases
(chronic, accelerated and blastic phases) at the time of
diagnose and follow up: IM-responsive patients (3 to 6 mo
follow up) and IM-resistant or relapse after initial response
(3 to 24 mo follow up). We selected 6 healthy donors
(mean age =30, range =20-37, male:female ratio = 4:2), 6
IM-responsive patients (mean age = 45, range = 35–68,
male:female ratio = 1:5) and 8 IM-resistant patients (mean
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ses and follow-ups were based on hematologic, cytogenetic
and molecular assays. IM-responsive patients exhibited a
major molecular response and complete hematologic and
cytogenetic response, whereas IM-resistant patients lacked
hematologic, cytogenetic and molecular responses. The in-
clusion criterion was to investigate CML patients that re-
ceived IM as a first-line therapy. The exclusion criterion
was CML patients with BCR-ABL mutations. Marrow aspi-
rates were collected in heparinized tubes and processed on
the day they were collected. Bone marrow mononuclear
cells were isolated from 2–5 mL of aspirate in a Ficoll-
Hypaque density gradient (Ficoll 1.077 g/mL; GE, Sweden)
according to manufacturer’s protocol. Cells were washed 3
times in PBS and subsequently used for RNA extraction.
Small interfering RNA (siRNA)
TK562 cells were plated at 1 × 105 cell/ml in a 24-well
plate and left overnight in RPMI-1640 media without
antibiotics. STATIP1 siRNA (100 nM) (SC-44436, Santa
Cruz) and 2 μL of Lipofectamine™ RNAiMAX (Invitro-
gen) were incubated separately in a final volume of
50 μL of RPMI-1640 media for 5 min. Subsequently, the
siRNA and Lipofectamine were mixed and incubated for
30 min and then applied dropwise on cell cultures.
Scrambled siRNA (100 nM) (SC-37007, Santa Cruz) was
used as an siRNA negative control. FITC-conjugated
siRNA (SC-36869, Santa Cruz) was used to evaluate the
transfection efficiency by FACS. siRNA transfections
were conducted for up to 72 h.
Proliferation assay
K562 cells (1 × 105) were transfected with scrambled or
STATIP1 siRNA in a 24-well plate for 72 h. After transfec-
tion, cell cultures were treated with 1 μM IM for 24 h.
WST-1 assay was performed to determine the number of
viable cells. The relative number of viable cells was
expressed as a percentage of the untreated cells.
Real time quantitative PCR (RT-qPCR)
Total RNA was extracted from IM-treated and untreated
cells using TRIzol reagent (Invitrogen). Total RNA was
subjected to treatment with a DNAse Amplification
Grade I Kit (Invitrogen) for the removal of DNA contam-
ination. Complementary DNA synthesis was performed
with Superscript-II Reverse Transcriptase (Invitrogen) fol-
lowing the manufacturer’s protocol. Quantitative Real-
Time PCR (RT-qPCR) was performed with SYBR Green
Master Mix (Invitrogen) in a Rotor-Gene Q (Qiagen). The
following forward (Fow) and reverse (Rev) primers were
used: STAT3 - Fow 5’ GGGAGAGAGTTACAGGTTGG
ACAT 3’, Rev 5’ AGACGCCATTACAAGTGCCA 3’;
STATIP1 - Fow 5’ CCACTGTCCCTGCATTGGGATT 3’,
Rev 5’ GCCACCTGCTGATACTCAAA 3’; CCND1- Fow5’ AGAGACCAGGCTGTGTCCCTC 3’, Rev 5’ GTGGT
GGCACGTAAGACACAC 3‘; BCL-XL Fow 5’ CTGGGG
TCGCATTGTGGC 3’, Rev 5’ AGCCGCCGTTCTCCTG
GA 3’; ABCB1 - Fow 5’ CCCATCATTGCAATAGCAGG
3’, Rev 5’ GTTCAAACTTCTGCTCCTGA 3’; ACTB -
Fow 5’ ACCTGAGAACTCCACTACCCT 3’, Rev 5’ GG
TCCCACCCATGTTCCAG 3’. The PCR cycling condi-
tions included an initial denaturation of 95°C for 10 mi-
nutes, followed by 45 cycles of 20 seconds at 95°C,
20 seconds at 60°C, and 40 seconds at 72°C. The β-actin
mRNA levels were used as a reference of expression. The
fold-expression was calculated according to Schmittgen
and Livak [32]. The primer sequences used in this work
are available upon request.
Western blot
Whole-cell protein extracts were obtained from cell lines in
lysis buffer containing 50 mM Tris pH 7.5, 5 mM EDTA,
10 mM EGTA, 50 mM NaF, 20 mM b-glycerolphosphate,
250 mM NaCl, 0.1% Triton X-100, 20 mM Na3VO4 and
protease inhibitor mix (Amersham). The protein concen-
trations were determined using the Bradford assay, and
30 μg of the cell lysate proteins was subjected to separation
by 10% SDS-PAGE. The protein extracts were electrophor-
etically transferred to a nitrocellulose membrane (GE) and
probed with the appropriate antibodies. The western
blots were developed by ECL Plus (Amersham). The fol-
lowing antibodies were used at 1:1000 dilutions: anti-
STATIP1, anti-STAT3, anti-STAT3-Y705 and anti-
ACTNB (Santa Cruz).
Immunofluorescence
K562 cells were fixed to glass slides using cytospin and
further fixed by immersion in methanol:acetic acid (1:1)
for 10 min at -20°C. Fixed cells were permeabilized in
0.5% Triton X-100 for 10 minutes and blocked with 5%
BSA for 1 h. Primary antibody incubation was performed
at 4°C for 16 h. The cell nuclei were stained with DAPI
(Santa Cruz). The images were analyzed using a LSM
510 Meta (Carl Zeiss) microscope equipped with a 63×/
1.4 NA Plan-Apochromat oil immersion objective.
Apoptosis assay
To determine the percentage of apoptotic cells, we analyzed
phosphatidyl serine externalization and membrane integrity
by double staining with Annexin V PE and 7-AAD (PE
Annexin V Apoptosis Detection Kit I, BD Pharmingen,
USA) according to manufacturer's instructions. Briefly, after
treatment, 1.0 × 105 cells were harvested, washed twice with
cold PBS and resuspended in 100 μL of 1× binding buffer.
Annexin V PE (5 μL) and 7-AAD (5 μL) were added, and
samples were incubated for 15 min in the dark. After incu-
bation, 400 μL of 1X binding buffer was added to each sam-
ple. Cells positive for Annexin V PE and 7-AAD were
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events were acquired using a FACSCalibur Flow Cyt-
ometer (Becton Dickinson, USA) and analyzed using
CellQuest v.3.1 Software (Becton Dickinson, USA). All
experiments were performed in triplicate.
Cell cycle assays
Cell cycle was evaluated by staining with propidium iod-
ide (PI, Sigma-Aldrich) [33]. Approximately 3.0 × 105
cells were resuspended in 400 μL of hypotonic buffer
(3.4 mM Tris-HCl (pH 7.6), 10 mM NaCl, 0.1% (v/v)
NP-40, 700 U/L RNase, and 0.075 mM PI) and incu-
bated for 30 min at 4°C. For every condition, 5.000
events were acquired in a FACSCalibur Flow Cytometer
(Becton Dickinson, USA) and analyzed using Cell Quest
v.3.1 Software (Becton Dickinson, USA). All experiments
were performed in triplicate.
Statistical analysis
All of the experiments were repeated at least three
times, and the data are expressed as the mean ± SD.
Statistical analyses (ANOVA and t-test) were performed
using GraphPad Prism® v.5 software (GraphPad). A
P-value (p) <0.05 was considered statistically significant
(*p <0.05, **p <0.01, ***p <0.001).
Results
Evaluation of STAT3 expression and phosphorylation in
CML K562 cells
Previous studies have demonstrated that STAT3 is con-
stitutively activated in a variety of cancer cell types [7],
including leukemic cells [34]. First, we evaluated the
STAT3 expression and phosphorylation status and sub-
cellular localization in our CML cell line, K562. For this,
immunofluorescence assays and western blot analyses
were performed. Our results indicate that STAT3 is pref-
erentially localized in the K562 cytoplasm, while a very
strong nuclear accumulation of phosphorylated STAT3
is observed in these cells (Figure 1F, 1I). These findings
indicate that when STAT3 is phosphorylated, it accumu-
lates in the K562 cell nucleus. These data validate our
model as a STAT3-activated leukemic cell line, as re-
ported by Benekli and cols. [7], who described STAT3
phosphorylation as a common finding in leukemic and
other cancer cells.
Inhibition of BCR-ABL interferes with STAT3 modifications
but does not alter STATIP1 protein expression
To demonstrate the role of BCR-ABL in STAT3 phos-
phorylation and the possible consequence of this signaling
on STATIP1 expression, we first investigated the status of
STAT3 and STATIP1 expression and STAT3 tyrosine-705
phosphorylation in BCR-ABL-inhibited K562 cells by im-
munofluorescence assays and western blotting. Weinhibited BCR-ABL activity with 1 μM IM (Figure 1J-R),
as previously described [35]. Although BCR-ABL coordi-
nates several molecular alterations, the STATIP1 protein
levels remained unaltered following BCR-ABL inhib-
ition using 1 μM IM for 24 h (Figure 1C, 1L). However,
the STAT3 protein levels, phosphorylation status and
nuclear accumulation were decreased in IM-treated
cells compared with non-treated K562 cells (Figures 1R
and 2A, C-D). Unlike STAT3, our data suggested that
STATIP1 expression is not related to BCR-ABL signal-
ing (Figures 1L and 2A, C-D).
Imatinib treatment induces down-regulation of STAT3 target
genes but not alteration of STATIP1 transcript levels
Several genes listed as STAT3 targets exhibit a relevant
role in cancer [7-10]. STAT3 target genes mainly include
cellular growth promoters and inhibitors of apoptosis
[36]. Moreover, STAT3 has been described as an activa-
tor of its own transcription [37]. Here, we investigated
the regulation of STAT3 target genes in K562 cells in re-
sponse to IM treatment. The mRNA levels of CCND1,
BCL-XL and STAT3 genes were measured by RT-qPCR.
Our results suggest that STAT3 target genes were down-
regulated 24 h after IM treatment (Figure 2A). To assess
the direct activity of STAT3 on its gene targets, we dir-
ectly inhibited STAT3 using LLL-3. In corroboration
with the previous results, the CCND1, BCL-XL and
STAT3 mRNA levels were down-regulated in K562 cells
after 24 h with LLL-3 treatment compared to untreated
cells (Figure 2B). These findings indicate that STAT3 inhib-
ition either indirectly, by IM, or directly, by LLL-3, induces
a decrease in STAT3 transcriptional activity. Additionally,
STAT3 inhibition with LLL-3 also does not interfere with
the STATIP1 mRNA levels (Figure 2B). Our data indicated
that STATIP1 is not correlated with either the BCR-ABL
or STAT3 signaling pathways but that it may be related to
STAT3 activity in the CML cell line.
STATIP1 depletion results in increased STAT3
transcriptional activity in K562 cells
Previous studies have demonstrated that STAT3 activity
can be regulated by STAT3 protein interactions [23,27,38].
To determine the potential of STATIP1 in regulating the
transcriptional activity of STAT3, K562 cells were
transfected with siRNA against STATIP1. The mRNA
levels were analyzed and compared to untransfected or
scrambled-transfected K562 cells. By RT-qPCR, signifi-
cant decreases in the STATIP1 mRNA and protein
levels were observed 72 h after siRNA transfection
(Figure 3A,B). Interestingly, the increase in STAT3
mRNA levels after STATIP1 inhibition were inversely
proportional, showing significant elevation at 72 h
(Figure 3C). This result suggests that with transient
STATIP1 depletion, STAT3 is more transcriptionally
Figure 1 Immunofluorescence analyses of STAT3, STAT3-Y and STATIP1 proteins. STAT3, STAT3-Y and STATIP1 FITC-labeled antibodies
(green), DAPI-stained DNA (blue) and merged images. Protein labeling was observed in untreated K562 cells (A-I) and K562 cells treated with
1 μM IM (J-R). The slides were analyzed using an LMS confocal system, and the images were processed using AxioVision-LE software (Carl Zeiss).
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STAT3 target gene mRNA levels. Surprisingly, in re-
sponse to STATIP1 inhibition, a significant two-fold
increase of CCND1 mRNA levels and a three-fold in-
crease of BCL-XL mRNA levels were observed 72 h
after siRNA transfection (Figure 3D). These findings
showed that STATIP1 down-regulation in K562 cells aug-
ments the STAT3 mRNA levels and its targeted genes,demonstrating that STATIP1 is involved (directly or indir-
ectly) in the negative regulation of STAT3 transcription.
STATIP1 is involved in imatinib resistance in CML
The role of STATIP1 both physiologically and in cancer
cells is completely unknown. In an effort to determine
the mechanism of STATIP1-mediated CML therapy re-
sistance, we used the Lucena cell line as a model of IM
Figure 2 Expression levels of STATIP1, STAT3, CCND1 and BCL-XL genes in response to IM/LLL-3 treatments. (A) Relative mRNA levels of
STATIP1, STAT3, CCND1 and BCL-XL after 24 h of 1 μM IM treatment. (B) Relative mRNA levels of STATIP1, STAT3, CCND1 and BCL-XL after 24 h of
40 μM LLL-3 treatment. (C) Western blot analysis of STAT3 and STATIP1 protein levels and STAT3-Y705 phosphorylation 24 h after 1 μM IM treatment.
(D) The protein levels were determined by densitometry analysis in ImageJ software version 1.44. All comparisons were made to untreated cells – ctrl.
Ctrl: control. The data represent the mean ± SD of at least three independent experiments (*p <0.05 and **p <0.01).
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3, and co-treatment (as previously reported) [35], and
the STAT3, STATIP1 and ABCB1 mRNA levels were
evaluated after 24 h and compared to untreated cells.
The STATIP1 mRNA levels were lower in the Lucena
cells compared to untreated K562 cells (Figure 4A).
Additionally, the STAT3 mRNA levels decreased by 60%
in the Lucena cells with each of the different treatments
(Figure 4B), but the ABCB1 mRNA levels only decreased
with the LLL-3 treatment (≅50%) (Figure 4C). No differ-
ences were observed regarding the ABCB1 mRNA levels
in K562 cells (data not shown). Interestingly, STAT3 in-
hibition by LLL-3 treatment sensitized Lucena cells to IM
treatment (Figure 4D) in a cell cycle arrest-independent
manner (Figure 4E-F). Together, these results suggest that
IM resistance may be associated not only with STAT3
overexpression/activation but also with STATIP1 down-
regulation.To address this hypothesis, we assessed K562 cell via-
bility after IM treatment in STATIP1-depleted cells 72 h
after siRNA transfection. Our results indicated a de-
crease in the IM sensitivity of the K562 cell line with re-
duced STATIP1 expression compared to the control or
scrambled K562 cells (Figure 5). After 24 h of 1 μM IM
treatment, approximately 25% of the STATIP1-depleted
K562 cells remained viable compared to the control or
scrambled cells (Figure 5). Additionally, we also analyzed
a total of 14 CML patients with different responses to
IM (6 IM-responsive and 8 IM-resistant) and 6 healthy
bone marrow donors. RT-qPCR analyses showed that
IM-resistant patients presented STATIP1 mRNAs levels
down-regulated, compared to IM-responsive patients
(Figure 6A). Moreover, STAT3 mRNA levels were in-
versely expressed; up-reguleted in IM-resistant patients,
compared to IM-responsive (Figure 6B). These data sug-
gest that the decreased expression of STATIP1 may
Figure 3 STATIP1 mRNA depletion by siRNA induces the over-expression of STAT3 and its target genes. (A) STATIP1 mRNA levels at 24 h,
48 h and 72 h after STATIP1 silencing, as determined by RT-qPCR. (B) Western blot analyses of the STATIP1 protein level 72 h after STATIP1
silencing. (C) RT-qPCR analyses of the STAT3 mRNA levels at 24 h, 48 h and 72 h after STATIP1 silencing. (D) RT-qPCR analyses of the CCND1 and
BCL-XL mRNA levels at 72 h after STATIP1 silencing. All comparisons were made to untreated cells – ctrl and scrambled-treated cells. Ctrl: control.
The data represent the means ± SD of at least three independent experiments (*p <0.05 and **p <0.01).
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be an important piece of in vivo IM-resistance develop-
ment in CML.Discussion
Although the BCR-ABL oncoprotein, a hallmark of
CML, constitutively activates multiple signaling path-
ways [3], our group was particular interested in STAT3
signaling activation, as the constitutive activation of
STAT3 is associated with oncogenic transformation in-
duced by the viral Src oncoprotein [2]. Furthermore,
many in vivo and in vitro assays have demonstrated the
association of STAT3 activation with the development
and maintenance of several cancer types [1,4,10,16].
Despite the known association of STAT3 phosphoryl-
ation with cancer, the mechanisms that regulate STAT3
are not well understood.In this study, we were able to clarify the relationship
between BCR-ABL signaling and STAT3 activation. Our
data indicated strong STAT3 phosphorylation and nuclear
accumulation in untreated K562 cells. K562 treatment with
IM, an inhibitor of BCR-ABL activity, not only promoted a
decrease in the mRNA and protein levels of STAT3 but
also inhibited STAT3 phosphorylation. Moreover, our re-
sults also showed a transcriptional positive feedback loop,
suggesting that STAT3 promotes its own over-expression,
which may be important to signaling intensification. In
summary, our findings suggest that STAT3 is phosphory-
lated and transcriptionally activated by BCR-ABL activity
in K562 cells.
Several studies have demonstrated that STAT3 signaling
can regulate the expression of numerous genes that are
frequently involved with proliferation and apoptosis [34],
angiogenesis, metastasis and differentiation [36], some of
which are capable of positively regulating STAT3 through
Figure 4 Involvement of STATIP1 and STAT3 genes in IM resistance in CML cell lines. (A) STATIP1 mRNA levels in K562 and Lucena cells
determined by RT-qPCR. (B) STAT3 mRNA levels, as determined by RT-qPCR, in Lucena cells under the following conditions: 1 μM IM treatment,
40 μM LLL-3 treatment, and co-treatment after 24 h. (C) The ABCB1 mRNA levels in Lucena cells were determined by RT-qPCR under the treatment
conditions noted above. (D) Apoptotic cells were measured by flow cytometry in both cell lines under the treatment conditions noted above. The cell
cycle was evaluated by flow cytometry after being subjected to the treatment conditions noted above in K562 (E) and Lucena (F) cells. All comparisons
were made to untreated cells – ctrl. Ctrl: control. The data represent the mean ± SD of at least three independent experiments (*p <0.05 and
**p <0.01).
Figure 5 Evaluation of cell viability in STATIP1-silenced K562
cells after IM treatment.The relative percentage of viable cells was
determined by WST-1 assay after 24 h of IM treatment (+), compared
to untreated cells – ctrl and scrambled-treated cells. Ctrl: control.
The data represent the mean ± SD of at least three independent
experiments (*p <0.05 and **p <0.01).
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STAT3 activation in BCR-ABL-inhibited cells, we assessed
the expression of representative known STAT3 target genes
involved in proliferation and cellular survival, CCND1 and
BCL-XL, respectively, and STATIP1, a protein identified in
a two-hybrid assay as interacting with STAT3 [29]. As ex-
pected, CCND1 and BCL-XL were down-regulated in re-
sponse to IM treatment, but unlike STAT3, the STATIP1
mRNA and protein levels were unaltered in the treated
cells. Accordingly, our results indicated that STATIP1 was
not affected by the molecular alterations promoted by
BCR-ABL signaling.
Hawkes and cols. characterized the STATIP1 levels in
the cytoplasm and nuclei of cancer cell lines exercising
multiple distinct roles that are dependent on its sub-
cellular localization [40]. To further investigate the rela-
tionship between STAT3 and STATIP1 in the context of
BCR-ABL, we inhibited STAT3 activity with LLL-3, a
more direct approach that has been previously used by
our group [35]. Similar to the BCR-ABL inhibition experi-
ments, previously investigated STAT3 target genes dem-
onstrated decreased mRNA levels compared to untreated
cells. STATIP1 remained unchanged in K562 cells treated
with the STAT3 drug inhibitor LLL-3. This result corrobo-
rates our previous results, again suggesting that STATIP1
expression is not related to molecular signaling changes
driven by either BCR-ABL or STAT3. Moreover, our
Figure 6 Expression levels of STATIP1 and STAT3 genes in CML patients. (A) STATIP1 mRNA levels and (B) STAT3 mRNA levels were
determined by RT-qPCR analyses in 6 IM-responsive patients and 8 IM-resistant patients. Raw expression values were normalized to β-actin expression.
Expression changes were calibrated by 6 healthy bone marrow donors analysis. Resp. P = responsive patients; Resist. P. = resistant patients. (*p <0.05).
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plasm and nuclei of K562 cells. Further characterization of
the localized STATIP1 pools could reveal its precise role
in these cellular compartments.
It is known that STATIP1 contains 12 WD40 domains
that are responsible for mediating protein-protein inter-
actions that play important roles in signal transduction
regulation, transcription and proteolysis [30]. In this
context, the investigation of the role of STATIP1 in sig-
nal transduction showed that its forced over-expression
is able to block STAT3 activation [29]. However, the
regulation of STAT3 transcriptional activity by STATIP1
was only observed in the human hepatocellular carcin-
oma cell line HepG2 [29]. In this study, we characterized
STATIP1 in the K562 cell line and investigated its role
in STAT3 transcriptional activity in a distinct cell line
established from another cancer type, chronic myeloid
leukemia. Instead of over-expressing STATIP1, as was
performed by Collun and cols. [29], we depleted the
STATIP1 mRNA and protein levels to investigate the
role of STATIP1 in regulating STAT3 transcriptional ac-
tivity in K562 cells. Our results showed a gradual in-
crease of STAT3-target gene mRNA levels, such as those
of STAT3, CCND1 and BCL-XL, in K562 cells subjected
to STATIP1 inhibition. Similarly to Collun [29], our
findings also indicated that STATIP1 may work as a
negative regulator of STAT3 transcriptional activity. Be-
cause STATIP1 interacts with STAT3, we inferred that
this may be a direct regulation mechanism. Indeed,
existing data have already characterized STATIP1 pro-
tein as a scaffolding protein that regulates the activity of
interacting proteins [40]. Based on this finding, we
propose that STATIP1 may interact with STAT3 in K562
cells and regulate STAT3 activation. However, additional
investigation is required to address the intricate mechan-
ism by which STAT3 is inhibited by STATIP1. Neverthe-
less, independent of whether it is a direct or indirect
regulation and how it works precisely, our resultsdemonstrated that negative regulation of STAT3 by
STATIP1 appears to be a common issue in distinct can-
cer cell types. If this result is validated in other diverse
cancer cell types, we propose that STAT3 regulation
may be important to cancer development and that it
may also be an interesting target for the design of new
drug strategies against cancer cells.
Because STAT3 over-expression is closely related to
CML drug resistance and has been implicated in a poor
prognosis [17,41], we evaluated the role of STATIP1 in IM
resistance. We took advantage of an IM-resistant cell
model, the Lucena cell line. Lucena cells exhibit a multi-
drug resistance phenotype (with ABCB1 over-expression)
and have been shown to also be IM resistant, compared to
K562 cells [39]. We investigated the STATIP1, STAT3, and
ABCB1 mRNA levels, together with apoptosis and cell
cycle arrest, in Lucena cells with the inhibition of BCR-
ABL and STAT3.
We observed decreased STATIP1 mRNA levels in
Lucena cells compared to K562 cells. Because Lucena cells
are resistant to IM, we observed STAT3 down-regulation
in all of the treatments; additionally, we observed a de-
crease in the ABCB1 mRNA levels. This result was ex-
pected because it is known that ABCB1 is a STAT3 target
[42,43]. Moreover, STAT3 direct inhibition (LLL-3 treat-
ment) induced Lucena cells to undergo apoptosis, in con-
trast to indirect inhibition (IM treatment), and this effect
was independent of cell cycle arrest. This result demon-
strated that STAT3 over-expression together with STA-
TIP1 down-regulation could be involved in IM resistance.
To validate this hypothesis, we depleted STATIP1 and
inhibited BCR-ABL activity in K562 cells and assessed the
proliferation and survival. Interestingly, our results dem-
onstrated that STATIP1-depleted K562 cells have a higher
survival percentage than control or scrambled-transfected
cells. STAT3 can overcome sensitivity to BCR-ABL inhib-
ition by driving proliferation, anti-apoptosis and MDR
gene expression, increasing CML cell survival [15-19,43].
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http://www.biomedcentral.com/1471-2407/14/866Moreover, althought we analyzed a small cohort of healthy
donors and patients samples, our in vivo analyses sug-
gested that STAT3 and STATIP1 genes are inversely
expressed in IM-response, which corresponds to our find-
ings in K562 and Lucena cell lines. The present study is
the first report of STATIP1 expression in CML patients
with different responses to IM therapy. Further studies
may reveal the details of STATIP1 role in IM resistance.
Conclusions
Our data suggest that STATIP1 may be a negative regu-
lator of STAT3 and that it could be involved in the ac-
quisition of therapeutic resistance to IM in CML.
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